High Circulating Sclerostin Level as Osteoporosis Risk Factor in Male Geriatric Population at Sanglah Hospital Bali

Sandra Suryarini; RA. Tuty Kuswardhani; I. Gusti Lanang Ngurah Agung Artha Wiguna

doi:10.3889/oamjms.2021.6944

Authors

Sandra Suryarini Internal Medicine Education Program, Faculty of Medicine, Udayana University, Bali, Indonesia https://orcid.org/0000-0003-0787-9110
RA. Tuty Kuswardhani Internal Medicine Education Program, Faculty of Medicine, Udayana University, Bali, Indonesia; Department of Internal Medicine, Geriatric Division, Sanglah General Hospital, Denpasar, Bali, Indonesia
I. Gusti Lanang Ngurah Agung Artha Wiguna Department of Orthopedic and Traumatology, Spine Orthopedic Division, Sanglah General Hospital, Denpasar, Bali, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2021.6944

Keywords:

Male, Geriatric, Osteoporosis, Sclerostin

Abstract

BACKGROUND: Osteoporosis is a disease characterized by low bone mass and structural deterioration of bone tissue, leading to bone fragility. The development of biomolecular world found Wnt/β-catenin signaling pathway may plays an important role in bone mass regulation. Osteoporosis in geriatric population remains one of global health problems and typically thought of as a disease impacting women, but recently increasing attention is being paid to osteoporosis in males. Osteoporosis in male accounts for higher morbidity and mortality compare to woman population. The association between sclerostin serum and risk for osteoporosis in male geriatric will be described as follows.

METHODS: This study is a case–control study with a total 54 samples of male geriatrics, divided into 27 non- osteoporosis subjects and 27 osteoporosis subjects (age ≥60 years old). Diagnosis of osteoporosis was defined according to the WHO criteria based on bone mineral density. All participants were scanned on a GE lunar prodigy bone densitometer. Sclerostin serum level was measured using enzyme-linked immunosorbent assay (ELISA).

RESULTS: The average age from total 54 samples in case group was 69.81 ± 6.5 years old and control 69.41 ± 5.97 years old. Cutoff value based on receiver operating characteristic curve for sclerostin serum level was 302.5 pg/mL where the sensitivity and specificity for developing osteoporosis in male geriatrics were 59.3% and 81.5%, respectively. Male geriatrics with sclerostin serum ≥302.5 pg/mL is 6.4 times more likely to developed osteoporosis than those with sclerostin serum <302.5 pg/mL (OR = 6.4; p = 0.0020; CI 95% = 1.856–22.068). Multivariate logistic regression analysis after controlling other variables such as bone mass index, age, smoking status, alcohol consumption, physical activity, sun exposure, and type II diabetes mellitus showed that high sclerostin level was an independent susceptibility factors for osteoporosis in male geriatrics population (p = 0.001).

CONCLUSIONS: This study showed that high circulating sclerostin serum (≥302.5 pg/mL) was risk factor for developing osteoporosis in male geriatrics.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

World Health Organization. Indonesia: Life Expectancy. Geneva: World Health Organization; 2017.

Moester MJ, Papapoulos SE, Löwik CW, van Bezooijen RL. Sclerostin: Current knowledge and future perspectives. Calcif Tissue Int. 2010;87:99-107. https://doi.org/10.1007/s00223-010-9372-1 PMid:20473488 DOI: https://doi.org/10.1007/s00223-010-9372-1

Yavropoulou M, Xygonakis C, Lolou M, Karadimou F, Yovos J. The sclerostin story: From human genetics to the development of novel anabolic treatment for osteoporosis. Hormones (Athens). 2014;13(4):323-37. https://doi.org/10.14310/horm.2002.1552 PMid:25555179 DOI: https://doi.org/10.14310/horm.2002.1552

D’Amelio P, Isaia GC. Male osteoporosis in the elderly. Int J Endocrinol. 2015;2015:907689. PMid:26457082 DOI: https://doi.org/10.1155/2015/907689

Brahm H, Mallmin H, Michaëlsson K, Ström H, Ljunghall S. Relationships between bone mass measurements and lifetime physical activity in a Swedish population. Calcified Tissue Int. 1998;62(5):400-12. https://doi.org/10.1007/s002239900452 PMid:9541517 DOI: https://doi.org/10.1007/s002239900452

Jackuliak P, Payer J. Osteoporosis, fractures, and diabetes. Int J Endocrinol. 2014;2014:820615. PMid:25050121 DOI: https://doi.org/10.1155/2014/820615

Raveendran A, Raveendran A, Khandelwal N, Sen RK, Thakur JS, Dhaliwal LK, et al. Prevalence and related risk factors of osteoporosis in peri- and postmenopausal Indian women. J Midlife Health. 2011;2(2):81-7. https://doi.org/10.4103/0976-7800.92537 PMid:22408337 DOI: https://doi.org/10.4103/0976-7800.92537

Damaso Ê, de Paula FJ, Franceschini SA, Vieira CS, Ferriani RA, de Sá MF, et al. Does the access to sun exposure ensure adequate levels of 25-hydroxyvitamin D? Rev Bras Ginecol Obstet. 2017;39(3):102-9. https://doi.org/10.1055/s-0037-1600520 PMid:28297731 DOI: https://doi.org/10.1055/s-0037-1600520

Bhattoa HP, Wamwaki J, Kalina E, Foldesi R, Balogh A, Antal- Szalmas P. Serum sclerostin levels in healthy men over 50 years of age. J Bone Miner Metab. 2013;31(5):579-84. https://doi.org/10.1007/s00774-013-0451-z PMid:23525828 DOI: https://doi.org/10.1007/s00774-013-0451-z

Zou J, Li X, Yang F. Association between sclerostin, serum bone turnover markers and bone density in postmenopausal women with fragility fracture. Int J Clin Exp Med. 2016;9(7):12984-91. https://doi.org/10.1002/jbmr.217

Mödder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, et al. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res. 2011;26(2):373-9. PMid:20721932 DOI: https://doi.org/10.1002/jbmr.217

Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532-43. https://doi.org/10.1056/nejmoa1607948 PMid:27641143 DOI: https://doi.org/10.1056/NEJMoa1607948

Lewiecki EM, Blicharski T, Goemaere S, Lippuner K, Meisner PD, Miller PD, et al. A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J Clin Endocrinol Metab. 2018;103(9):3183-93. https://doi.org/10.1210/jc.2017-02163 PMid:29931216 DOI: https://doi.org/10.1210/jc.2017-02163

Kuo TH, Lin WH, Chao JY, Wu AB, Tseng CC, Chang YT, et al. Serum sclerostin levels are positively related to bone mineral density in peritoneal dialysis patients: A cross-sectional study. BMC Nephrol. 2019;20(1):266-74. https://doi.org/10.1186/s12882-019-1452-5 PMid:31315601 DOI: https://doi.org/10.1186/s12882-019-1452-5

Lapauw B, Vandewalle S, Taes Y, Goemaere S, Zmierczak H, Collette J. Serum sclerostin levels in men with idiopathic osteoporosis. Eur J Endocrinol. 2013;168(4):615-20. https://doi.org/10.1530/eje-12-1074 PMid:23389587 DOI: https://doi.org/10.1530/EJE-12-1074